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 CURRENTOPINION Fibroblasts in atherosclerosis: heterogeneous and
plastic participants
Renée J.H.A. Tilliea, Kim van Kuijka, and Judith C. Sluimera,b
Purpose of review
Fibroblasts are very heterogeneous and plastic cells in the vasculature. A growing interest in fibroblasts in
healthy and atherosclerotic vasculature is observed, next to macrophages, endothelial cells, and smooth
muscle cells (SMCs). In this review, we discuss fibroblast presence, heterogeneity, origin, and plasticity in
health and atherosclerosis based on latest literature.
Recent findings
With help of single cell sequencing (SCS) techniques, we have gained more insight into presence and
functions of fibroblasts in atherosclerosis. Next to SMCs, fibroblasts are extracellular matrix-producing cells
abundant in the vasculature and involved in atherogenesis. Fibroblasts encompass a heterogeneous
population and SCS data reveal several fibroblast clusters in healthy and atherosclerotic tissue with varying
gene expression and function. Moreover, recent findings indicate interesting similarities between adventitial
stem and/or progenitor cells and fibroblasts. Also, communication with inflammatory cells opens up a new
therapeutic avenue.
Summary
Because of their highly plastic and heterogeneous nature, modulating fibroblast cell function and
communication in the atherosclerotic vessel might be useful in battling atherosclerosis from within the
plaque.
Keywords
atherosclerosis, fibroblast, mesenchymal cell
INTRODUCTION
Atherosclerosis and its clinical manifestations, for
example myocardial infarction and stroke, are cur-
rently still the leading causes of death worldwide [1].
Atherosclerosis is characterized by lipid accumula-
tion in the subendothelial space, intimal inflamma-
tion, smooth muscle cells (SMC) migration from the
media to the outside of the newly formed plaque
and ultimately plaque rupture [2]. Different cell
types, including endothelial cells, macrophages,
and SMCs, play prominent roles in this life-long
process [3–5]. However, recent evidence suggests
that an additional cell type, the fibroblast, is an
important player in matrix production in athero-
sclerosis. Traditionally, fibroblasts are thought to
arise from mesenchymal stem cells (MSCs) and are
thus part of the mesenchymal cell category, also
including pericytes and SMCs. In arterial injury,
adventitial fibroblasts differentiate into activated
fibroblasts (myofibroblasts) with de-novo alpha-
smooth muscle actin (a-SMA) expression in
response to proinflammatory cytokines, matrix
remodeling, and transforming growth factor beta
(TGF-b) signaling. Myofibroblasts have been impli-
cated in extracellular matrix (ECM) production,
proinflammatory cytokine, and matrix metallopro-
teinase (MMP) secretion and leukocyte recruitment
[6–8]. However, these traditional views are being
overturned by new insights and the advent of single
cell sequencing (SCS), which will be discussed in
this review.
In fact, the ability to acquire stem cell properties
by upregulating markers such as stem cell antigen-1
(Sca-1) enables fibroblasts to be plastic and
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adaptable in numerous environmental situations
[9
&
,10]. Because of this heterogeneity and plasticity,
currently used markers seem insufficient in unique
identification of fibroblasts and/or covering the
whole fibroblast population. Here, SCS will aid to
find markers unique to fibroblasts. Indeed, SCS of
healthy mouse brain confirmed the traditional
marker platelet-derived growth factor alpha (Pdgfra)
and yielded three new markers, decorin, lumican,
and Mmp2 [11]. However, both lumican and
decorin have been associated with other cell types
involved in the advent of atherosclerosis [12
&&
,13].
This may suggest disease and/or organ specificity of
markers to identify fibroblasts. The lack of a one-
size-fits-all marker makes investigating their role in
atherosclerosis development challenging. In this
review, we aim to elucidate the functional role of
fibroblasts in healthy and atherosclerotic vascula-
ture by discussing fibroblast presence, heterogene-
ity, origin, and plasticity.
FIBROBLASTS IN HEALTHY
VASCULATURE
The arterial wall consists of three layers. The inner
intima is composed of an endothelial cell mono-
layer. The middle medial layer consists of SMCs
embedded in ECM. Finally, the adventitia is the
outer layer and is traditionally thought to harbor
mesenchymal cells, that is fibroblasts, pericytes and
SMCs, connective tissue, unmyelinated nerve fibers,
resident leukocytes, small blood vessels with endo-
thelial cells surrounded by mesenchymal cells, and
several progenitor cells [8]. Multiple studies have
shown the fibroblast’s potential to extensively par-
ticipate in organ homeostasis and repair mecha-
nisms in response to stress [14–16]. The
emergence of SCS has provided researchers the
opportunity to study vascular cells in more depth.
This technique has improved fibroblast annotation
and revealed different subsets in multiple organs.
Kalluri et al. [17
&&
] used abovementioned technique
to investigate all three layers of the healthy murine
aorta. The authors showed that SMCs comprise the
largest cell population in the murine aorta (40%),
but surprisingly, also showed that fibroblasts make
up for roughly 33% of aortic cells [17
&&
]. These
fibroblasts consist of two subpopulations, with a
phenotypic gradient rather than a rigid split
between them. These fibroblasts are probably
derived from the adventitia, although the authors
removed perivascular fat – possibly including the
adventitia. As their arterial wall location was not
validated by immunohistochemistry or in-situ
hybridization, a possible medial location for one
or both subpopulations is yet to be confirmed. Fur-
thermore, their function, embryonic origin, cellular
progeny and fate are yet unknown. Gu et al. studied
the adventitia of healthy murine aorta and shed
more light on their function. They uncovered four
mesenchymal populations, whose differential gene
expression suggests functions in ECM organization,
immune regulation and bone formation [18
&&
].
These data suggest fibroblast heterogeneity, already
present in a healthy steady state.
FIBROBLASTS IN ATHEROSCLEROSIS
The classical dogma in atherogenesis entails migra-
tion of medial SMCs to the newly formed plaque,
producing ECM components for fibrous cap forma-
tion [2]. This dogma has recently been challenged,
as several groups have reported the presence of
fibroblast-like cells in human atherosclerotic lesions
[12
&&
,19]. Also, adventitial fibroblast-like cells have
been functionally implicated in plaque ECM pro-
duction [19,20]. Using ApoE/ mice on a Western
diet superimposed with chronic kidney disease, Kra-
mann et al. [20] showed that a subset of adventitial
MSC-like cells, expressing GLI family zinc finger 1
(Gli1), Sca1, and PDGFRb, migrated into the media
and neointima. Gli1þ cells contributed to calcifica-
tion by differentiation into osteoblast-like cells. In
contrast, Evrard et al. [19] reported decreased colla-
gen and increased MMP expression in another sub-
set of endothelial-derived, fibroblast-like cells
expressing fibroblast activation protein (Fap) or
fibroblast-specific protein 1 (Fsp1, S100a4 gene) in
atherosclerosis, indicating a role in matrix degrada-
tion. In 2019, a key paper by Wirka et al. [12
&&
]
employed SCS to assess cellular composition in ath-
erosclerotic plaques from human coronary artery
and mouse aorta, and identified two fibroblast clus-
ters. Interestingly, Gli1, Fap, or Fsp1 were not
among the top 100 differential genes in the two
murine or human fibroblast subsets defined by
Wirka, complicating the interpretation of the
above reference studies and strongly suggesting
KEY POINTS
 Fibroblasts are ECM-producing cells abundant in the
vasculature and involved in atherogenesis.
 Fibroblasts encompass a very heterogeneous
population as indicated by SCS data revealing several
fibroblast clusters in healthy and atherosclerotic tissue
with varying gene expression and function.
 Fibroblast identity has been proposed for adventitial
progenitor and/or stem cells and should be
further investigated.
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heterogeneity. Together, these studies suggest that
fibroblast clusters identified in healthy and diseased
tissue differ in functionality, possibly because of




As described above, varying numbers of fibroblast
clusters with corresponding differential gene sets
have been identified in healthy and atherosclerotic
tissue. Additionally, studies in other organs have
shown that new fibroblast clusters can arise as a
consequence of disease, further supporting plastic-
ity and heterogeneity [15]. Heterogeneity makes it
very difficult to identify the entire fibroblast popu-
lation and a resulting lack of specific markers com-
plicates fibroblast research. Common fibroblast
markers, such as FAP, FSP1, and lumican are not
specifically expressed by fibroblast-like cells only,
and/or are not expressed by all fibroblasts [21–25].
Fibroblast heterogeneity may be a result of their
various origins and enormous plasticity, all
enhanced as a result of adaptation to disease. Here,
we describe evidence to support that fibroblasts in
atherosclerosis may also originate from SMCs and/
or endothelial cells (Fig. 1). Also, we discuss adven-
titial stem and/or progenitor cells as a source of
fibroblasts or possibly a subset of fibroblasts.
Smooth muscle cells origin
Wirka et al. studied SMC differentiation and their
contribution to atherosclerosis in vivo combining
SCS and a fluorescent myosin heavy chain 11
(Myh11) reporter strain for SMCs on an ApoE/ back-
ground. In contrast to prevailing concepts of myofi-
broblast development from fibroblasts, they reported
SMC differentiation into fibroblast-like, ‘fibromyo-




on chow, a Myh11þ SMC cluster appeared and
expanded with HFD feeding. This modulated SMC
cluster showed decreased expression of SMC differen-
tiation markers, and a clear transcriptional shift
towardsgenesexpressedbythe fibroblastclusters, later
confirmed in human coronary arteries [12
&&
]. Never-
theless, the cells were transcriptionally distinct from
fibroblasts and displayed the Myh11-reporter. These
data highlighted the benefits of fluorescent fate track-
ing and lead one to wonder whether these fibroblast-
like cells have reached the end stage of their dediffer-
entiation or will dedifferentiate further into actual
fibroblasts. Another question is, does the differentia-
tion also occur the other way around? Comparison
between the modulated SMC cluster and a myofibro-
blastpopulationcouldbeinterestingtoavoidoff-target
effects in future cell-specific targeting.
Endothelial origin
Another possible fibroblast source are endothelial
cells, which can undergo endothelial-to-mesenchy-
mal transitioning (EndMT). A review by Kovacic et al.
[26
&
] emphasized the functional importance of
EndMT in both healthy and diseased vasculature.
EndMT results in downregulation of endothelial-
associated genes, such as cluster of differentiation
31 (CD31) or VE-cadherin, and upregulation of mes-
enchymal genes, such as a-SMA and FAP. These cells
genetically present as mesenchymal cells and can
execute mesenchymal functions like ECM produc-
tion [26
&
]. Evrard et al. [19] specifically showed that
fibroblasts can arise through EndMT in atherosclero-
sis. Using a tamoxifen-inducible endothelial lineage-
tracking system in ApoE/mice, they observed one-
third of plaque cells positive for Fap were endothelial-
derived after 8 weeks of HFD. The population
expanded to nearly 50% in advanced atherosclerotic
plaques [19]. They showed that EndMT is stimulated
in vitro by severe hypoxia, TGF-b signaling, and oxi-
dative stress, factors that are ubiquitous in athero-
sclerosis [19]. Oscillatory shear stress has also been
identified as EndMT inducer in atherosclerosis [27].
Importantly, Evrard et al. [19] uncovered a relation-
ship between the extent of EndMT and an unstable
plaque phenotype in humans. Notably, the data
should be interpreted with slight caution, as the
markers used to identify fibroblasts are not unique
[23,24]. Current SCS publications have not explicitly
reported on EndMT, either because it was unstudied
or possibly because of lack of sufficient cells to model
transitions. However, the reported two fibroblast
human subsets could include EndMT-derived cells.
The top 100 differential genes do not include endo-
thelial markers, yet this does not exclude low marker
expression [12
&&
]. Hence, SCS using endothelial cell
reporter strainsareyet to fully confirm these findings.
In addition, the functional differences between both
EndMT-derived and SMC-derived fibroblast (-like)
cells and their exact contribution to atherosclerosis
remain to be elucidated.
Adventitial stem and/or progenitor cells
Fibroblasts have been suggested to originate from a
pool of adventitial stem and/or progenitor cells. How-
ever, the identity of these cells is a point of discussion,
as fibroblasts also have the ability to re-acquire stem
cell properties by upregulating markers such as Sca-1
[9
&
,10,20,28]. Additionally, MSCs and fibroblasts are
Fibroblasts in atherosclerosis Tillie et al.
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morphologically similar and expression of MSC sur-
face markers, such as CD105, CD73, and CD90, has
been observed on fibroblasts. Vice versa, MSC expres-
sion of common fibroblast markers, that is vimentin
and fibroblast surface protein (FSP) has been reported
[9
&
]. Similar to MSCs, fibroblasts seem capable of dif-
ferentiation into adipogenic, osteoblastogenic, and
chondrogenic lineages [9
&
]. These insights might sug-
gest thatadventitial MSCs andSca-1þprogenitor cells,
previously identified and studied by many groups, are
in fact fibroblasts. Indeed, a recent paper by Ni et al.
shows that 10% of c-Kitþ cells was positive for the
fibroblast marker PDGFRA in healthy C57Bl6 aorta
[29
&
]. Their findings were confirmed using an induc-
ible Cre model, labeling c-Kitþ cells with TdTomato,
showing 20% overlap between PDGFRA and c-Kit
[29
&
]. Moreover, Tang et al. [21,30
&
] also reported that
40% of adventitial Sca-1þ cells with progenitor prop-
erties coexpressed PDGFRA. These Sca-1þ/PDGFRAþ,
progenitor-like cells generated new medial SMCs after
severe artery injury [30
&
]. Similar to other recent stud-
ies that assessed vasculature cell populations by SCS,
Gu et al. [18
&&
] did not annotate mesenchymal clusters
inadventitiaofApoE/ andwildtypeaortasas stemor
progenitor cells. Yet, one of the four identified mes-
enchyme clusters showed high Sca-1þ expression,
indicating stem cell properties of this cluster [18
&&
].
The distinction between true adventitial stem and/or
progenitor cells and fibroblasts may thus be smaller
than previously assumed, and expression of Sca1þ
indicative of fibroblast plasticity.
Together, these data suggest that fibroblasts show
an even greater plasticity than previously thought.
Cell transitioning of fibroblasts into other cell types
and vice versa seems common and extensive in ath-
erosclerosis. Whether all currently identified adventi-
tial stem and/or progenitor cells are really adventitial
fibroblasts and vice versa is an important remaining
question to be resolved using reliable fibroblast
reporter models. Based on this concept, another ques-
tion is whether the fibroblast is an end-stage cell or
merely a collection of heterogeneous ‘in between’
cells, actively transitioning between different cell
types, or a combination of the two. It would be inter-
esting to study if the acquisition of stem cell-like
properties by fibroblasts occurs through dedifferenti-
ation. Assessing the differentiation capacity of the
distinct fibroblast clusters into other cell types could




In addition to heterogeneity and function of fibro-
blasts in the natural development of atherosclerosis,
these cells could possibly be used as a new therapeutic
approach based on their effect on surrounding
inflammatory cells. A proinflammatory role of mes-
enchyme clusters through increased intercellular
communication with inflammatory macrophages
has been computationally predicted in ApoE/
adventitia by Gu et al. [18
&&
]. A recent paper by Gorabi
et al. [31
&
] also reviewed the possibility of using MSCs
as treatment for atherosclerosis by modulating
inflammation. Multiple studies discussed in this
review showed a marked anti-inflammatory effect
in murine atherosclerosis by decreased proinflamma-
tory cytokines and nuclear factor-kappa B signaling
afterbonemarrow MSCadministration.MSCtherapy
has been studied in clinical trials for diseases such as
heart disease, cancer and peripheral artery disease,
but not atherosclerosis. It is considered a promising
future treatment option, but at the same time its
safety and efficacy are questioned. Knowledge regard-
ing precise in-vivo mechanisms of action is still lack-
ing and inconsistent results are observed because of
cellular heterogeneity of MSCs and a lack of specific
markers [32]. Donor characteristics, culture condi-
tions, method and location of delivery, and host
receptibility are all factors that can influence MSC
therapy efficacy and efficiency [31
&
,32,33]. More-
over, risks of malignant transformation and protu-
morigenic effects of MSCs have been reported. Thus,
extensive additional research into improving effi-
ciency and efficacy of MSC therapy is required before
considering this a new therapy option.
CONCLUSION AND FUTURE RESEARCH
The present review shows that in contrast to the
assumptions the classical dogmas contain, next to
SMCs, fibroblasts are ECM-producing cells abundant
in the vasculature and involved in atherosclerosis.
Fibroblasts comprise a very heterogeneous popula-
tion because ofdifferentcellularoriginsandanexten-
sive repertoire of possible cell transitions. The origin
and fate of fibroblasts in atherosclerotic plaques
remains to be elucidated. Because of their heteroge-
neity, there is a lack of specific markers that encom-
pass the entire population making it difficult to study
fibroblast (sub)populations in atherosclerosis. Recent
comparisons between fibroblasts and adventitial
stem and/or progenitor cells indicate similarities
between these cells. Moreover, recent SCS data did
not identify any adventitial stem and/or progenitor
cell clusters, supporting fibroblast identity of these
cells. SCS data did identify multiple fibroblast clusters
with differential gene expression and functionality
per cluster in healthy and atherosclerotic tissue. Fur-
ther research into subpopulations of fibroblasts and
their different functions is needed to identify specific
Fibroblasts in atherosclerosis Tillie et al.
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markers per subpopulation and to determine the
contribution of each subpopulation to atherosclero-
sis. The emergence of SCS provides opportunities to
find answers to the remaining questions in an unbi-
ased way. In the future, modulating fibroblast cell
communication in atherosclerotic vessels could be
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